To The Moon

$Pfizer(PFE)$

Pfizer's stock is currently trading near its 52-week low, down about 5% over the past year. Looking at the bigger picture, it's also trading close to its lowest level in the past decade. This price point presents Pfizer's highest starting dividend yield in 10 years, currently around 6.64%.

At first glance, the stock appears attractive. Its Forward price-to-earnings (P/E) ratio is just 8.62—significantly lower than the average S&P 500 company. Additionally, analysts from Seeking Alpha, Wall Street, and Quant all give Pfizer a "Buy" rating. However, a deeper analysis reveals several concerns, especially following Pfizer’s latest earnings report and 2025 outlook.

Earnings Overview

For the full year 2024, Pfizer reported $63.6 billion in revenue, reflecting 7% year-over-year operational growth. However, revenues have dropped significantly from pandemic-era highs—$81.2 billion in 2021 and a peak of $100 billion in 2022. While 2024 revenue slightly exceeds pre-pandemic levels, it remains well below the COVID-driven peak.

Currently, Pfizer's stock is trading at the same level it was back in 2006–2007, which is shocking for a company of this size. In their last earnings report, Pfizer actually posted a solid beat, reporting earnings of $0.63 per share versus the expected $0.46. Revenue also exceeded expectations, primarily due to stronger-than-anticipated COVID-19 vaccine sales.

One positive takeaway from the earnings report is Pfizer’s gross profit ratio. After declining sharply post-2020—hitting a low of 49.2% in 2023—it rebounded to approximately 72% in 2024, aligning closer to the company’s 10-year average.

On the other hand, earnings per share (EPS) for 2024 came in at $1.42—an improvement from $0.38 in 2023 but still significantly lower than previous years. Despite beating expectations on both top and bottom lines, the stock has continued to decline.

Fundamental Analysis

The company is implementing significant cost-cutting measures, targeting $4.5 billion in savings by the end of 2025. These efforts should help improve margins. However, Pfizer has not repurchased any stock in 2024, which has contributed to its weak performance. Generally, when companies halt buybacks—like Dollar General, for example—it signals trouble. Pfizer, despite trading at an attractive valuation with a 13% free cash flow yield, hasn’t been able to buy back shares due to its high debt load, mainly from its Seagen acquisition.

Pfizer has prioritized debt reduction, paying down $7.8 billion while also maintaining its $9.5 billion annual dividend. This financial burden means stock buybacks are unlikely in 2025 as well, with deleveraging continuing into that year. However, buybacks could resume in late 2025 or 2026, potentially marking a turning point for the stock.

Following its Seagen acquisition, Pfizer has become a leader in oncology, a rapidly growing sector in the healthcare industry. While this positions the company well for the long term, there are risks ahead. One major concern is the upcoming loss of exclusivity (LOE) on key patents between 2026 and 2028, which is expected to reduce revenue by $17–18 billion—about 30% of Pfizer’s total revenue. However, the company expects recently acquired products to generate $20 billion in revenue by 2030, potentially offsetting these losses and driving modest growth.

Guidance

Pfizer has provided its financial guidance for full-year 2025, projecting revenues between $61.0 billion and $64.0 billion. This forecast includes expectations that COVID-19 product revenues in 2025 will remain consistent with 2024 levels, excluding approximately $1.2 billion of non-recurring revenues from 2024. The company also anticipates adjusted diluted earnings per share (EPS) for 2025 to range from $2.80 to $3.00, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance, after adjusting for non-recurring items.

In terms of operational revenue growth, Pfizer expects a year-over-year increase ranging from flat to 5% from the midpoint of its 2024 baseline guidance, excluding non-recurring items. This projection accounts for an anticipated net unfavorable impact of approximately $1 billion due to changes in the Inflation Reduction Act (IRA) Part D redesign, effective in 2025.

The company has achieved its goal of $4.0 billion in net cost savings through 2024 from its ongoing cost realignment program and anticipates an additional $500 million in savings in 2025. Additionally, the first phase of Pfizer's Manufacturing Optimization Program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance.

For full-year 2025, Pfizer projects adjusted Selling, Informational & Administrative (SI&A) expenses between $13.3 billion and $14.3 billion, and adjusted Research & Development (R&D) expenses ranging from $10.7 billion to $11.7 billion. This results in total adjusted SI&A and R&D expenses between $24.0 billion and $26.0 billion for the year.

In its recent announcement, Pfizer also reaffirmed its full-year 2024 guidance, maintaining revenue expectations between $61.0 billion and $64.0 billion, with adjusted EPS projected between $2.75 and $2.95.

Why Is Pfizer Stock Trading at a Decade Low?

One major concern is Pfizer’s 2025 revenue guidance, which projects revenues between $61 billion and $64 billion—essentially flat year-over-year.

Another issue is Pfizer’s capital allocation. The company returned $9.5 billion to shareholders through cash dividends in 2024, an increase from $9.25 billion in 2023. However, free cash flow for 2023 was just $4.7 billion, meaning dividend payments exceeded free cash flow for the first time in a decade. This raises concerns about dividend sustainability.

Historically, Pfizer has maintained a steady dividend growth rate—5% CAGR over the past decade and 3.25% over the past five years. However, in 2023, the company’s net income was only $8 billion—less than what it paid out in dividends. Since dividends must be funded from earnings, questions about long-term sustainability are valid.

The company has acknowledged the need to optimize capital allocation, prioritizing reinvestment in the business and debt reduction. Notably, Pfizer did not repurchase any shares in 2024, despite trading at a decade low. The company’s financial position simply doesn’t allow for buybacks at this time.

Pipeline Challenges and Patent Expirations

Pfizer faces a critical period of patent expirations over the next three years, which management estimates will cost the company around 30% of its trailing 12-month revenue—approximately $18 billion. To counter this, Pfizer acquired cancer drug maker Seagen for $43 billion in 2023, expecting it to contribute $3.1 billion in 2024 revenue. While this strengthens Pfizer’s oncology segment, it may not be enough to offset the impending revenue loss from expiring patents.

Regulatory Risks

Investors are also concerned about potential regulatory challenges. The "Make America Healthy Again" initiative aims to increase transparency and accountability for pharmaceutical companies. While details remain unclear, stricter regulations could present further obstacles for Pfizer.

Free Cash Flow

From an investment standpoint, assuming Pfizer returns 100% of its free cash flow to shareholders—through dividends (6%) and potential buybacks (6%)—investors could see an annual return of around 12%, excluding multiple expansion. If the stock’s valuation multiple improves due to new drug discoveries or market conditions, returns could be even higher—potentially 14–17% annually.

Dividend

Regarding the dividend, Pfizer currently offers a 6.6% yield, one of its highest since 2013. The company’s free cash flow yield for 2025 is projected at 12.6%, meaning the dividend payout ratio is around 50%. Management has repeatedly stated their commitment to maintaining the dividend, and given the cash flow outlook, it appears sustainable. With the remaining free cash flow, Pfizer can continue reducing debt, repurchasing shares, or even increasing the dividend in the future.

Is Pfizer Undervalued or a Value Trap?

Benjamin Graham’s valuation model, based on estimated earnings per share (EPS) and growth projections, suggests an intrinsic value of approximately $24 per share—very close to the stock’s current trading price.

Similarly, the Dividend Discount Model (DDM), which values the stock based on dividend payments and expected growth, estimates a fair price of $26.52 per share. When averaging these two models, Pfizer’s estimated intrinsic value is around $25.20 per share—just 1.5% above the current stock price. With a 10% margin of safety, a reasonable buy price would be $22.74 per share.

Conclusion

Ultimately, for investors seeking a stable dividend stock with a 6% yield and the potential for 12–13% annual returns, Pfizer appears to be a solid option. However, those looking for higher growth might want to consider other investments.

Pfizer’s low valuation, high dividend yield, and analyst buy ratings may make it appear attractive. However, the company faces significant long-term challenges, including slowing revenue growth, expiring patents, and potential regulatory risks. While some headwinds, like government policies, may be short-term, structural issues such as declining revenue and dividend sustainability are more concerning.

For me personally, Pfizer is not a stock I’m interested in at this time, and I believe its dividend may be at risk in the coming years. What do you think? Let me know in the comments.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub